Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-02-08
2005-02-08
Russel, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S011400, C514S014800, C514S016700, C514S051000, C514S567000
Reexamination Certificate
active
06852688
ABSTRACT:
The subject invention provides novel methods and materials for treating diabetic retinopathy. One embodiment of the subject invention involves the co-administration of a somatostatin, or analogue thereof, and a thryoid-related substance such as thyroxine. Somatostatin or thyroid-related substance can be administered in combination, or separately through the same or different modes of administration.
REFERENCES:
patent: 4863457 (1989-09-01), Lee
patent: 4997652 (1991-03-01), Wong
patent: 5098443 (1992-03-01), Parel et al.
patent: 5164188 (1992-11-01), Wong
patent: 5185152 (1993-02-01), Peyman
patent: 5378475 (1995-01-01), Smith et al.
patent: 5384333 (1995-01-01), Davis et al.
patent: 5443505 (1995-08-01), Wong et al.
patent: 5554187 (1996-09-01), Rizzo, III
patent: 5583224 (1996-12-01), Riese
patent: 5710145 (1998-01-01), Engel et al.
patent: 5710182 (1998-01-01), Reunamaki et al.
patent: 5718922 (1998-02-01), Herrero-Vanrell et al.
patent: 5719175 (1998-02-01), Heath, Jr. et al.
patent: 5725493 (1998-03-01), Avery et al.
patent: 5919813 (1999-07-01), De Juan, Jr.
patent: 6440933 (2002-08-01), Bodor et al.
Grant et al. Octreotide Retards Progression of Diabetic Retinopathy in Patients Treated with Thyroid Hormone. Diabetes. 1999, vol. 48, Suppl. 1, pp. A155-A156, Abstract No. 0674.*
Anonymous,MMWR(1993) 42(10): 191-195.
Plewe, G. et al. “Somatostatin analogue SMS 201-995 in type I diabetes mellitus. Initial experience after repeated administration.”Scand J Gastroenterol Suppl.(1986) 119: 166-169.
Klein, et al.Opthalmol.(1984) 91: 10-17.
Merimee, T.J.New England Journal of Medicine.(1990) 322: 978-983.
Murphy,American Family Physician(1995) 51(4): 785-796.
Rohrer, et al. “Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry”Science.(1998) 282: 737-740.
Patel and Srikant,Endocrinology.(1994) 135(6): 2814-7.
Valli, et al.Opthalmologica.(1995) 209(13): 117-121.
ASHP Handbook on Injectable Drugs.Trissel, 4thed. (1986) 622-630.
Aiello, et al.PNAS USA.(1995) 92: 10457-10461.
DHAR, et al.,Mol. Pharmacol.(1990) 37: 519-525.
Asahi, et al.FEBS Letter.(1992) 309: 10-14.
Tomlinson, et al.Pharmac. Ther.(1992) 54: 151-194.
The Diabetic Retinopathy Study Research Group “Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report No: 14”Int. Opthalmol. Clin.(1987) 27: 239.
Early Treatment Diabetic Retinopathy Study Research Group “Techniques for scatter and local photocoagulation treatment of diabetic retinopathy. Early Treatment Diabetic Research Study Report No. 3”Int. Opthamol Clin.(1987) 27: 254-264.
Kirkegaard, et al. “Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in Type-1 (insulin-dependent) diabetes mellitus”Acta Endocrinol(Copenh) (1990) 122: 766-72.
Colas, et al., “Stimulation of a membrane tyrosine phosphatase activity by somatostatin analogues in rat pancreatic acinar cells”Eur. J. Biochem.(1992) 207: 1017-1024.
Leszczynski, et al. “Rat heart smooth muscle cells express high and low affinity receptors for somatostatin-14, which are involved in regulation of cell proliferation”Life Sci.(1993) 53: 1663-1674.
Grant, et al. “Inhibition of IGF-I and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment for ocular neovascularization”Regul Pept(1993) 48: 267-278.
Grant, et al.Diabetes.(1986) 35: 416-420.
Meyer-Schwickerath, et al.J. Clin. Invest.(1993) 92: 2620-2625.
Grant, et al.Ann Ny Acad Science.(1993) 692: 230-242.
Danis, et al.Opthalmology.(1997) 104: 1661-1669.
Amiel, et al.Diabetes.(1984) 33: 1175-1179.
Tan, et al.J. Clin. Endocrinol. Metab.(1986) 63: 651-655.
Kolaczynski, et al.Ann Inern Med.(1994) 120: 47-55.
Langford, et al.Eur. J. Clin. Invest.(1993) 23: 503-516.
Koller, et al.J. Clin Endocrinol Metab.(1998) 83: 2380-2383.
Aiello, et al.Diabetes.(1997) 46: 1473-1480.
Smith, et al.Science.(1997) 276: 1706-1709.
McCombe, M. et al. “Effect of long-acting somatostatin analogue (BIM23014) on proliferative diabetic retinopathy: a pilot study”Eye(1991) 5: 569-575.
Beusse Brownlee Wolter Mora & Maire
Russel Jeffrey Edwin
University of Florida
Van Dyke Timothy H.
LandOfFree
Compositions for treating diabetic retinopathy and methods... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions for treating diabetic retinopathy and methods..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for treating diabetic retinopathy and methods... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3464241